On November 12, 2020 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported that it will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT (Press release, Adaptimmune, NOV 12, 2020, View Source [SID1234570725]). A link to register is available HERE and further details are on the Investor Relations tab of the Adaptimmune website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by Adaptimmune’s Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center.